Holen Sie sich die Stockscreener-App
5.05
2.02%
0.10
Vorhandelsmarkt:
4.58
-0.47
-9.31%
Schlusskurs vom Vortag:
$4.95
Offen:
$7.24
24-Stunden-Volumen:
26.03M
Relative Volume:
59.83
Marktkapitalisierung:
$3.66M
Einnahmen:
$4.96M
Nettoeinkommen (Verlust:
$-6.82M
KGV:
-0.0772
EPS:
-65.4
Netto-Cashflow:
$-6.64M
1W Leistung:
+23.77%
1M Leistung:
+14.80%
6M Leistung:
-4.61%
1J Leistung:
-29.57%
1-Tages-Spanne:
$4.97
$8.27
1-Wochen-Bereich:
$4.07
$8.27
52-Wochen-Spanne:
$2.414
$15.70
Inmed Pharmaceuticals Inc Stock (INM) Company Profile
Firmenname
Inmed Pharmaceuticals Inc
Sektor
Branche
Telefon
(604) 669-7207
Adresse
1445-885 WEST GEORGIA ST., VANCOUVER
Vergleichen Sie INM mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
INM
Inmed Pharmaceuticals Inc
|
5.05 | 3.66M | 4.96M | -6.82M | -6.64M | -65.40 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Inmed Pharmaceuticals Inc Aktie (INM) Neueste Nachrichten
InMed Pharmaceuticals (NASDAQ: INM) Announces Positive Results from INM-901 Alzheimer’s Disease Study - Defense World
Nano-Cap InMed Ignites Retail Frenzy As Stock Soars After Alzheimer's Drug Trial Shows Promise - MSN
InMed Hails Alzheimer's Study, Stocks Shoot Higher - Baystreet.ca
InMed announces ‘positive’ results from in vivo preclinical Alzheimer’s study - TipRanks
InMed’s INM-901 Shows Promising Results in Preclinical Alzheimer’s Study - TipRanks
InMed's INM-901 Demonstrates Statistically Significant Reduction in Neuroinflammation in a Long-Term Preclinical Alzheimer's Disease Study - Newsfile
SABBY MANAGEMENT, LLC Acquires Shares in InMed Pharmaceuticals I - GuruFocus.com
InMed Pharmaceuticals Inc. Holds 2024 Annual General Meeting – Elects Directors and Appoints Auditor - Defense World
InMed Pharmaceuticals Director Faces Resignation After Shareholder Vote at Annual Meeting - StockTitan
InMed Announces Results of 2024 Annual General Meeting - Newsfile
InMed Pharmaceuticals Inc. announced that it expects to receive CAD 10 million in funding - Marketscreener.com
InMed Enters Into Standby Equity Purchase Agreement - Newsfile
Head-To-Head Review: InMed Pharmaceuticals (NASDAQ:INM) & Rocket Pharmaceuticals (NASDAQ:RCKT) - Defense World
InMed Pharmaceuticals Secures $10 Million Equity Purchase Agreement - TipRanks
InMed Pharmaceuticals (TSE:IN) Trading Down 1.6% – Time to Sell? - Defense World
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.86 (As of Dec. 05, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Altman Z-Score : -14.90 (As of Dec. 03, 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Inventories, Finished Goods : €0.84 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Shares Outstanding (EOP) : 0.67 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Total Liabilities : $2.07 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Debt-to-Equity : 0.13 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Dividend Payout Ratio : 0.00 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) EBITDA : $-6.66 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year Dividend Growth Rate : 0.00% (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Cash, Cash Equivalents, Marketa - GuruFocus.com
INM (InMed Pharmaceuticals) Growth Rank : 0 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Machinery, Furniture, Equipment : $0.04 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 3-Year EPS without NRI Growth R - GuruFocus.com
INM (InMed Pharmaceuticals) Total Inventories : $1.22 Mil (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Net Income : $-6.82 Mil (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Inventory Turnover : 0.63 (As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Revenue per Share : $49.03 (TTM As of Sep. 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Forward Dividend Yield % : 0.00% (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) 9-Day RSI : 44.83 (As of Nov. 26, 2024) - GuruFocus.com
INM (InMed Pharmaceuticals) Price-to-Operating-Cash-Flow : (As of Nov. 26, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Ending Cash Position : €5.03 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) EBITDA : €-6.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (FRA:MWG) Book Value per Share : €11.34 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Accounts Receivable : €0.26 Mil (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Pre-Tax Income : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Days Inventory : 147.82 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) GF Score : 43/100 (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Earnings per Share (Diluted) : €-59.16 (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Median PS Value : €0.00 (As of Nov. 21, 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Asset Turnover : 0.11 (As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Net Income From Continuing Operations : €-6.25 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Cost of Goods Sold : €3.11 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Intrinsic Value: DCF (Earni - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) Free Cash Flow : €-6.08 Mil (TTM As of Sep. 2024) - GuruFocus.com
InMed Pharmaceuticals (STU:MWG) COGS-to-Revenue : 0.61 (As of Sep. 2024) - GuruFocus.com
Finanzdaten der Inmed Pharmaceuticals Inc-Aktie (INM)
Umsatz
Nettogewinn
Free Cashflow
ENV
4.81%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):